Shandong Boan Biotechnology hits record high on drug's commercialization hope

Shandong Boan Biotechnology

14/03/2023 04:59

** Shares of China's biopharmaceuticals group Shandong Boan
Biotechnology Co Ltd  6955.HK  soar as much as 70.7% to
HK$25.20, their highest and biggest daily pct gain since debut
on Dec 30
    ** Stock is the third biggest pct gainer on the Hong Kong
bourse
    ** Shandong-based therapeutic antibodies developer says its
Aflibercept Intravitreous Injection (BA9101) has completed
patient enrollment for its phase 3 clinical study in China for
comparing the efficacy and safety of BA9101 
    ** Says it has partnered with Ocumension Therapeutics
 1477.HK  in conducting the phase 3 clinical study and has
granted Ocumension an exclusive right to commercialize BA9101 in
mainland China
    ** Says the collaboration with Ocumension will accelerate
the clinical trials and commercialization of BA9101 
    ** Shares of Ocumension Therapeutics rise 2.7%
    ** The Hang Seng Commerce & Industry Index  .HSNC  eases
1.7% and the Hang Seng Index  .HSI  falls 1.8%, while the
healthcare index  .HSCIH  climbs 0.6% 


 (Reporting by Donny Kwok)
 ((donny.kwok@thomsonreuters.com))